PF-06281355

PF-06281355

Biochem/physiol Actions

PF-06281355 (PF-1355) is an orally available, selective and potent mechanism based inhibitor of the myeloperoxidase (MPO) that reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevated circulating cytokines. PF-06281355 suppresses albuminuria and chronic renal dysfunction in model of anti-Glomerular Basement Membrane (GBM) disease.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Nitric Oxide & Cell Stress research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3573684 PF-06281355 white to beige 100 SIGMA-ALDRICH room temp DMSO: 10 mg/mL, clear (warmed) powder ≥98% (HPLC)
£427.61 (exc VAT) per 25MG
-
+
3573685 PF-06281355 white to beige 100 SIGMA-ALDRICH room temp DMSO: 10 mg/mL, clear (warmed) powder ≥98% (HPLC)
£132.88 (exc VAT) per 5MG
-
+